Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | STAT6 | P42226 | 1/20 | 0.33 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28262550 | 0.91 | GRIN2D (0.36) | LMNAGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6235075 | 0.72 | HSD11B1 (0.34) | HSD11B1 | |
| SCHEMBL26934476 | 0.72 | — | — | |
| SCHEMBL870113 | 0.67 | GRIN2D (0.46) | LMNAGRIN2DGRIN3BGRIN1GRIN2A | |
| Bicarbonate SCHEMBL7739291 | 0.66 | HSD11B1 (0.36) | SIGMAR1THRBHSD11B1 | |
| Bicarbonate SCHEMBL7732897 | 0.66 | HSD11B1 (0.36) | SIGMAR1THRBHSD11B1 | |
| SCHEMBL15922722 | 0.66 | GRIN2D (0.36) | LMNAGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL25338011 | 0.65 | GRIN2D (0.38) | LMNAGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1015951 | 0.65 | GRIN2D (0.38) | LMNAGRIN2DGRIN3BGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL11127087 | 0.65 | LMNA (0.48) | LMNAGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140228375-A1 | SIGMA RECEPTORS LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES, OVER CELLULAR MECHANISMS, EXHIBITING PROTOTYPICAL CYTOPROTECTIVE AND ALSO ANTI-CANCER ACTIVITY | ANAVEX LIFE SCIENCES CORP. (US) | 2014-08-14 | — | — | US | claimed |
| EP-2400965-A1 | SIGMA( ) RECEPTORS LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES, OVER CELLULAR MECHANISMS, EXHIBITING PROTOTYPICAL CYTOPROTECTIVE AND ALSO ANTICANCER ACTIVITY | Vamvakides, Alexandre (GR) | 2012-01-04 | — | — | EP | claimed |
| WO-2010097641-A1 | SIGMA(σ) RECEPTORS LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES, OVER CELLULAR MECHANISMS, EXHIBITING PROTOTYPICAL CYTOPROTECTIVE AND ALSO ANTICANCER ACTIVITY | VAMVAKIDES ALEXANDRE (GR) | 2010-09-02 | — | — | WO | claimed |
| EP-2164479-A2 | NEW SIGMA-RECEPTOR LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES OVER CELLULAR BIOCHEMICAL MECHANISMS, WITH NEUROPROTECTIVE, ANTI- CANCER, ANTI-METASTATIC AND ANTI-(CHRONIC) INFLAMMATORY ACTION | Vamvakides, Alexandre (GR) | 2010-03-24 | — | — | EP | claimed |
| US-20100069484-A1 | SIGMA(s)-RECEPTOR LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES OVER CELLULAR BIOCHEMICAL MECHANISMS, WITH NEUROPROTECTIVE, ANTI-CANCER, ANTI-METASTATIC AND ANTI-(CHRONIC) INFLAMMATORY ACTION | ANAVEX LIFE SCIENCES CORP. (CH) | 2010-03-18 | — | — | US | claimed |
| WO-2008087458-A2 | NEW SIGMA(σ)-RECEPTOR LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES OVER CELLULAR BIOCHEMICAL MECHANISMS, WITH NEUROPROTECTIVE, ANTI-CANCER, ANTI-METASTATIC AND ANTI-(CHRONIC) INFLAMMATORY ACTION | VAMVAKIDES ALEXANDRE (GR) | 2008-07-24 | — | — | WO | claimed |
| US-20170129864-A1 | NEW SIGMA-RECEPTORS LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES, OVER CELLULAR BIOCHEMICAL MECHANISMS WITH NEUROPROTECTIVE, ANTI-CANCER, ANTI-METASTATIC AND ANTI-(CHRONIC) INFLAMMATORY ACTION | ANAVEX LIFE SCIENCES CORP. (CH) | 2017-05-11 | — | — | US | disclosed |
| US-20170129864-A1 | NEW SIGMA-RECEPTORS LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES, OVER CELLULAR BIOCHEMICAL MECHANISMS WITH NEUROPROTECTIVE, ANTI-CANCER, ANTI-METASTATIC AND ANTI-(CHRONIC) INFLAMMATORY ACTION | ANAVEX LIFE SCIENCES CORP. (CH) | 2017-05-11 | — | — | US | disclosed |
| US-9180106-B2 | Sigma receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular mechanisms, exhibiting prototypical cytoprotective and also anti-cancer activity | ANAVEX LIFE SCIENCES CORP. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9180106-B2 | Sigma receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular mechanisms, exhibiting prototypical cytoprotective and also anti-cancer activity | ANAVEX LIFE SCIENCES CORP. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140228375-A1 | SIGMA RECEPTORS LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES, OVER CELLULAR MECHANISMS, EXHIBITING PROTOTYPICAL CYTOPROTECTIVE AND ALSO ANTI-CANCER ACTIVITY | ANAVEX LIFE SCIENCES CORP. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228375-A1 | SIGMA RECEPTORS LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES, OVER CELLULAR MECHANISMS, EXHIBITING PROTOTYPICAL CYTOPROTECTIVE AND ALSO ANTI-CANCER ACTIVITY | ANAVEX LIFE SCIENCES CORP. (US) | 2014-08-14 | — | — | US | disclosed |
| CN-102325529-A | Sigma receptors with pro-apoptotic and/or anti-apoptotic properties in terms of cellular mechanisms showing prototypical cytoprotective activity and also showing anticancer activity | ALEXANDRE VAMVAKIDES | 2012-01-18 | — | — | CN | disclosed |
| WO-2010097641-A1 | SIGMA(σ) RECEPTORS LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES, OVER CELLULAR MECHANISMS, EXHIBITING PROTOTYPICAL CYTOPROTECTIVE AND ALSO ANTICANCER ACTIVITY | VAMVAKIDES ALEXANDRE (GR) | 2010-09-02 | — | — | WO | disclosed |
| EP-2164479-A2 | NEW SIGMA-RECEPTOR LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES OVER CELLULAR BIOCHEMICAL MECHANISMS, WITH NEUROPROTECTIVE, ANTI- CANCER, ANTI-METASTATIC AND ANTI-(CHRONIC) INFLAMMATORY ACTION | Vamvakides, Alexandre (GR) | 2010-03-24 | — | — | EP | disclosed |
| US-20100069484-A1 | SIGMA(s)-RECEPTOR LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES OVER CELLULAR BIOCHEMICAL MECHANISMS, WITH NEUROPROTECTIVE, ANTI-CANCER, ANTI-METASTATIC AND ANTI-(CHRONIC) INFLAMMATORY ACTION | ANAVEX LIFE SCIENCES CORP. (CH) | 2010-03-18 | — | — | US | disclosed |
| US-20100069484-A1 | SIGMA(s)-RECEPTOR LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES OVER CELLULAR BIOCHEMICAL MECHANISMS, WITH NEUROPROTECTIVE, ANTI-CANCER, ANTI-METASTATIC AND ANTI-(CHRONIC) INFLAMMATORY ACTION | ANAVEX LIFE SCIENCES CORP. (CH) | 2010-03-18 | — | — | US | disclosed |
| CN-101646430-A | Novel sigma-receptor ligands with anti-apoptotic and/or pro-apoptotic properties based on cellular biochemical mechanisms, with neuroprotective, anti-cancer, anti-metastatic and anti- (chronic) inflammatory effects | VAMVAKIDES ALEXANDRE GR | 2010-02-10 | — | — | CN | disclosed |
| WO-2008087458-A3 | NEW SIGMA(σ)-RECEPTOR LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES OVER CELLULAR BIOCHEMICAL MECHANISMS, WITH NEUROPROTECTIVE, ANTI-CANCER, ANTI-METASTATIC AND ANTI-(CHRONIC) INFLAMMATORY ACTION | VAMVAKIDES ALEXANDRE (GR) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008087458-A2 | NEW SIGMA(σ)-RECEPTOR LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES OVER CELLULAR BIOCHEMICAL MECHANISMS, WITH NEUROPROTECTIVE, ANTI-CANCER, ANTI-METASTATIC AND ANTI-(CHRONIC) INFLAMMATORY ACTION | VAMVAKIDES ALEXANDRE (GR) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069484-A1 | SIGMA(s)-RECEPTOR LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES OVER CELLULAR BIOCHEMICAL MECHANISMS, WITH NEUROPROTECTIVE, ANTI-CANCER, ANTI-METASTATIC AND ANTI-(CHRONIC) INFLAMMATORY ACTION | SIGMAR1, BAD, OPRK1 | LMNA 2215/4885GRIN2D 342/4885GRIN3B 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.